Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood tests, Epi+Gen CHD and PrecisionCHD, are now available at Family Medicine Specialists’ (FMS) newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois. FMS is a leading primary care and risk-bearing provider in Northern Illinois and in December 2023, launched the ongoing Heart Attack Prevention Initiative for at least 1,200 of their BlueCross BlueShield and other health plan patients. This launch in a retail healthcare setting is an expansion to existing and new patients in the area.

Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO, May 10, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from plasma. The translational study provides pre-clinical evidence to support Aethlon's planned phase 1 safety, feasibility and dose-finding clinical trials of the Hemopurifier in patients with solid tumors ...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Collaboration will Transition the Company from R&D to Commercialization REHOVOT, Israel, May 13, 2024 /PRNewswire/ -- Steakholder Foods Ltd. (Nasdaq: STKH), a leading innovator in alternative proteins and 3D printing technologies, announced a royalties and raw materials supply agreement with Wyler Farm Ltd., a leader in alternative protein production, whereby Wyler Farm will manufacture alternative proteins on a commercial scale using Steakholder Foods' premixes and know-how, in return for the payment of royalties from sales. The agreement is expected to generate the company's first commercial revenue, and marks Steakholder Foods' early transition from R&D to commercialization.